Objective: Present study aimed towards the development of a novel delivery system for pain management of rheumatic disorders. Materials and methods: An optimized solid dispersion (SD) of flurbiprofen was prepared using PEG 6000 at various ratios, of flurbiprofen and PEG 6000 i.e. 1:1, 1:2, 1:3, 1:4 and 1:5. The prepared SD formulations were optimized for solubility profile, Fourier Transform Infra-Red (FTIR) spectroscopy and differential scanning calorimetry (DSC). From IR, it may be concluded that there is change in crystalline form of drug into amorphous during formation of SD. From DSC studies, it was predicted that drug was completely dissolved in the carrier. Mouth dissolving tablets of flurbiprofen (MDTs) were formulated using optimized SD formulation of carrier: drug: polymer, (1:3) along with various super-disintegrants. Results and discussion: The developed batches of MDTs were characterized for micromeritic study, thickness, hardness, weight variation, wetting time, disintegration time, drug content and in vitro drug release profile. KT9 formulation containing 4% Kyron T-314 showed the best results with a wetting time and disintegration time of 28.3 and 38.3 sec, respectively. KT9 formulation showed superior drug release of 99.96% in comparison to 54.24% of conventional formulation over a period of 30 minutes. Conclusion: Preliminary results from the study suggested that this Solid dispersion entrapped MDTs can be used to incorporate other anti arthritic drugs and could be effective against Rhematoid Arthritis.